Related Experiment Video
Updated: Jul 3, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Potent and selective pyrazole-based inhibitors of B-Raf kinase
Joshua D Hansen1, Jonas Grina, Brad Newhouse
1Lead Optimization, Array BioPharma, 3200 Walnut Street, Boulder, CO 80301, USA. josh.hansen@arraybiopharma.com
Bioorganic & Medicinal Chemistry Letters
|August 5, 2008
Abstract:
Herein we describe a novel pyrazole-based class of ATP competitive B-Raf inhibitors. These inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. A subset of these inhibitors has demonstrated the ability to inhibit downstream ERK phosphorylation in LOX tumors from mouse xenograft studies.
Insights
Researchers developed new pyrazole-based drugs that effectively inhibit B-Raf kinase activity. These potent and selective inhibitors also reduced downstream signaling in preclinical cancer models.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- B-Raf is a key kinase in the MAPK signaling pathway, often mutated in various cancers.
- Targeting B-Raf with small molecule inhibitors has shown therapeutic promise.
- Developing selective inhibitors is crucial to minimize off-target effects.
Purpose of the Study:
- To discover and characterize a novel class of pyrazole-based ATP-competitive B-Raf inhibitors.
- To evaluate the cellular potency and selectivity of these novel inhibitors against B-Raf.
- To assess the in vivo efficacy of these inhibitors in reducing downstream signaling.
Main Methods:
- Synthesis and chemical characterization of pyrazole-based compounds.
- In vitro enzymatic assays to determine inhibitory activity and selectivity.
- Cellular assays to measure inhibition of B-Raf and downstream signaling.
- In vivo xenograft studies in mouse models using LOX tumors.
Main Results:
- Identification of a novel pyrazole-based chemical series targeting B-Raf.
- Demonstrated excellent cellular potency and high selectivity for B-Raf over other kinases.
- Observed significant inhibition of extracellular signal-regulated kinase (ERK) phosphorylation in LOX tumor xenografts.
Conclusions:
- The novel pyrazole-based inhibitors represent a promising new class of B-Raf-targeted therapeutics.
- These compounds display favorable potency and selectivity profiles.
- Preclinical data support their potential for treating B-Raf-driven cancers.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...